Cemiplimab, a human monoclonal antibody to PD-1, in patients with advanced cutaneous squamous cell carcinoma (CSCC): Clinical experience from the phase 1 and phase 2 studies
We report the combined clinical experience of cemiplimab in advanced CSCC in both studies (NCT02383212 and NCT02760498).
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
More News: Academies | Cancer & Oncology | Carcinoma | Dermatology | Skin | Skin Cancer | Squamous Cell Carcinoma | Study